Iron Triangle Partners LP Buys Shares of 130,000 Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Iron Triangle Partners LP has acquired a new stake in Jazz Pharmaceuticals, purchasing 130,000 shares valued at approximately $16.14 million, which now represents about 2.6% of their investment portfolio.
• Jazz Pharmaceuticals reported a loss of $8.25 earnings per share for the last quarter, which missed the consensus estimate, despite revenue being $1.05 billion, showing a 2.1% increase compared to the same quarter last year.
• The stock of Jazz Pharmaceuticals has been rated as a "Moderate Buy" by analysts, with a current average target price of $178.21.

Iron Triangle Partners LP acquired a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 130,000 shares of the specialty pharmaceutical company's stock, valued at approximately $16,140,000. Jazz Pharmaceuticals comprises about 2.6% of Iron Triangle Partners LP's investment portfolio, making the stock its 21st biggest position. Iron Triangle Partners LP owned about 0.21% of Jazz Pharmaceuticals as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Versant Capital Management Inc increased its holdings in Jazz Pharmaceuticals by 9.4% in the 1st quarter. Versant Capital Management Inc now owns 1,058 shares of the specialty pharmaceutical company's stock worth $131,000 after buying an additional 91 shares during the period. Kendall Capital Management raised its position in shares of Jazz Pharmaceuticals by 1.2% in the first quarter. Kendall Capital Management now owns 7,964 shares of the specialty pharmaceutical company's stock worth $989,000 after acquiring an additional 95 shares during the period. Louisiana State Employees Retirement System increased its stake in shares of Jazz Pharmaceuticals by 0.6% during the first quarter. Louisiana State Employees Retirement System now owns 16,900 shares of the specialty pharmaceutical company's stock worth $2,098,000 after purchasing an additional 100 shares in the last quarter. Sound View Wealth Advisors Group LLC boosted its stake in shares of Jazz Pharmaceuticals by 1.3% in the first quarter. Sound View Wealth Advisors Group LLC now owns 8,425 shares of the specialty pharmaceutical company's stock worth $1,046,000 after acquiring an additional 110 shares during the last quarter. Finally, Cardinal Capital Management boosted its stake in shares of Jazz Pharmaceuticals by 0.9% in the first quarter. Cardinal Capital Management now owns 13,254 shares of the specialty pharmaceutical company's stock worth $1,645,000 after acquiring an additional 114 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Robert W. Baird reduced their target price on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They issued a "buy" rating and a $152.00 price target for the company. Royal Bank Of Canada raised their price objective on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an "outperform" rating in a report on Thursday, August 28th. Piper Sandler restated an "overweight" rating and set a $147.00 target price (down from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $202.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, August 28th. Fourteen research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $178.67.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ traded up $1.96 during mid-day trading on Tuesday, hitting $129.71. 637,594 shares of the company were exchanged, compared to its average volume of 948,038. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. The stock has a 50 day simple moving average of $114.90 and a 200-day simple moving average of $116.93. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $148.06. The firm has a market cap of $7.87 billion, a price-to-earnings ratio of -19.27, a price-to-earnings-growth ratio of 8.04 and a beta of 0.24.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The business had revenue of $1.05 billion during the quarter, compared to analysts' expectations of $1.05 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The company's revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $107.63, for a total value of $107,630.00. Following the completion of the transaction, the chief executive officer owned 436,973 shares in the company, valued at approximately $47,031,403.99. This represents a 0.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.